Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Wadowski, PP; Steinlechner, B; Zimpfer, D; Schlöglhofer, T; Schima, H; Hülsmann, M; Lang, IM; Gremmel, T; Koppensteiner, R; Zehetmayer, S; Weikert, C; Pultar, J; Jilma, B.
Functional capillary impairment in patients with ventricular assist devices.
Sci Rep. 2019; 9(1):5909 Doi: 10.1038/s41598-019-42334-3 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Zimpfer Daniel
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: The implantation of continuous - flow ventricular assist devices (VAD) is suggested to evoke angiodysplasia contributing to adverse events such as gastrointestinal bleeding. We evaluated in vivo capillary density and glycocalyx dimensions to investigate possible systemic microvascular changes in patients with chronic heart failure and VAD support vs. standard medical treatment. Forty-two patients with VAD support were compared to forty-one patients with ischemic and non-ischemic chronic heart failure (CHF) on standard pharmacotherapy and to a group of forty-two healthy subjects in a prospective cross-sectional study. Sublingual microcirculation was visualized using Sidestream Darkfield videomicroscopy and functional and perfused total capillary densities were quantified. Patients with VAD implantation were followed for one year and bleeding events were recorded. Median time after VAD implantation was 18 months. Patients were treated with centrifugal-flow devices (n = 31) or axial-flow devices (n = 11). Median functional capillary density was significantly lower in patients with VAD therapy as compared to CHF patients (196 vs. 255/mm², p = 0.042, adjusted p-value). Functional and total capillary densities were 44% and 53% lower (both p < 0.001) in patients with VAD therapy when compared to healthy subjects. Cox regression analysis revealed loss of capillary density as a significant predictor of bleeding events during one -year follow-up of VAD patients (HR: 0.987, CI (95%): 0.977-0.998, p = 0.021 for functional and 0.992, CI (95%): 0.985-0.999, p = 0.03 for total capillary density). In conclusion, patients with VAD support exhibit capillary density rarefaction, which was associated with bleeding events. If confirmed independently, capillary impairment may be evaluated as novel marker of bleeding risk.
Find related publications in this database (using NLM MeSH Indexing): Aged - administration & dosage; Capillaries - pathology; Cardiomyopathies - pathology, therapy; Case-Control Studies - administration & dosage; Cross-Sectional Studies - administration & dosage; Female - administration & dosage; Follow-Up Studies - administration & dosage; Heart Failure - pathology, therapy; Heart-Assist Devices - adverse effects; Humans - administration & dosage; Male - administration & dosage; Microcirculation - administration & dosage; Microvascular Rarefaction - etiology, pathology; Middle Aged - administration & dosage; Myocardial Ischemia - pathology, therapy; Prognosis - administration & dosage; Retrospective Studies - administration & dosage